Great Lakes Advisors LLC Acquires New Holdings in Baxter International Inc. $BAX

Great Lakes Advisors LLC bought a new position in Baxter International Inc. (NYSE:BAX) in the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund bought 237,106 shares of the medical instruments supplier’s stock, valued at approximately $5,055,000.

A number of other large investors have also recently added to or reduced their stakes in BAX. Wealthfront Advisers LLC acquired a new position in Baxter International during the second quarter valued at approximately $300,000. Equity Investment Corp acquired a new stake in shares of Baxter International in the second quarter worth $146,815,000. Pzena Investment Management LLC bought a new stake in shares of Baxter International during the 2nd quarter worth $1,392,098,000. BlackRock Inc. bought a new stake in shares of Baxter International during the 2nd quarter worth $1,744,874,000. Finally, Deutsche Bank AG acquired a new position in Baxter International in the 2nd quarter valued at $44,167,000. Institutional investors own 90.19% of the company’s stock.

Analysts Set New Price Targets

Several research analysts recently commented on BAX shares. UBS Group lifted their target price on shares of Baxter International from $19.00 to $25.00 and gave the stock a “hold” rating in a report on Tuesday, July 28th. TD Cowen upped their price target on shares of Baxter International from $20.00 to $24.00 and gave the company a “hold” rating in a report on Monday, July 27th. Wells Fargo & Company raised their price target on Baxter International from $19.00 to $23.00 and gave the company an “equal weight” rating in a research report on Friday, July 31st. Wall Street Zen upgraded Baxter International from a “hold” rating to a “buy” rating in a research note on Saturday, August 1st. Finally, Stifel Nicolaus boosted their price objective on Baxter International from $19.00 to $24.00 and gave the stock a “hold” rating in a research report on Tuesday, July 28th. Two analysts have rated the stock with a Buy rating, nine have assigned a Hold rating and two have assigned a Sell rating to the stock. According to MarketBeat.com, Baxter International currently has an average rating of “Hold” and a consensus target price of $22.45.

Baxter International Trading Up 2.6%

Shares of Baxter International stock opened at $26.61 on Thursday. Baxter International Inc. has a 1 year low of $15.73 and a 1 year high of $30.00. The company’s fifty day simple moving average is $23.40 and its 200-day simple moving average is $20.27. The company has a market cap of $13.76 billion, a price-to-earnings ratio of -12.86, a PEG ratio of 3.92 and a beta of 0.60. The company has a current ratio of 1.95, a quick ratio of 1.32 and a debt-to-equity ratio of 1.39.

Baxter International (NYSE:BAX) last released its earnings results on Thursday, July 30th. The medical instruments supplier reported $0.56 EPS for the quarter, beating the consensus estimate of $0.37 by $0.19. Baxter International had a negative net margin of 9.27% and a positive return on equity of 16.57%. The firm had revenue of $2.96 billion during the quarter, compared to analysts’ expectations of $2.80 billion. During the same period in the prior year, the company earned $0.59 EPS. The business’s quarterly revenue was up 5.3% compared to the same quarter last year. Baxter International has set its FY 2026 guidance at 1.950-2.150 EPS. As a group, sell-side analysts expect that Baxter International Inc. will post 2.04 EPS for the current year.

Baxter International Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Thursday, October 1st. Stockholders of record on Friday, August 28th will be given a dividend of $0.01 per share. The ex-dividend date of this dividend is Friday, August 28th. This represents a $0.04 dividend on an annualized basis and a dividend yield of 0.2%. Baxter International’s dividend payout ratio is currently -1.93%.

Baxter International Company Profile

Baxter International Inc is a global healthcare company that develops, manufactures and markets a broad portfolio of medical products, pharmaceutical therapies and biotechnology-based solutions. The company’s primary business activities are organized around renal care, medication delivery, acute therapies, pharmacy automation, surgical care and biotechnology. Baxter’s offerings are designed to support patient care in hospitals, dialysis centers, nursing homes and other healthcare facilities worldwide.

In the renal care segment, Baxter provides hemodialysis and peritoneal dialysis systems, water treatment equipment and related disposables, including dialyzers, bloodlines and catheters.